NeuroPace Submits Three-Year Data from RNS System Post-Approval Study to FDA
Key Insights
NeuroPace has submitted three-year safety and effectiveness data to the FDA from its Post-Approval Study (PAS) of the RNS System (search) for drug-resistant focal epilepsy (search).
The RNS System (search) PAS is the largest prospective post-approval study in neuromodulation, involving over 300 patients with drug-resistant focal epilepsy (search) across multiple centers.
The study evaluates the RNS System (search)'s performance in adults with focal epilepsy (search), the most common form of drug-resistant epilepsy (search), with a five-year follow-up planned.
NeuroPace, Inc. (Nasdaq: NPCE) has announced the submission of three-year safety and effectiveness data from its Post-Approval Study (PAS) of the RNS System (search) to the Food and Drug Administration (FDA). The RNS System is designed for adults with drug-resistant focal epilepsy (search). The study, which enrolled over three hundred patients from more than thirty leading Level 4 Comprehensive Epilepsy (search) Centers in the United States, is the largest prospectively enrolled trial in the field of neuromodulation for drug-resistant focal epilepsy.
Study Details and Objectives
The RNS System (search) PAS is a five-year prospective, multicenter study required by the FDA to gather additional data on the safety and effectiveness of the RNS System as an adjunctive therapy for adult patients with drug-resistant focal epilepsy (search). The pre-specified primary effectiveness endpoint is at three years of treatment. The study aims to evaluate the safety and effectiveness of the RNS System in the adult focal population, which represents the largest patient segment of drug-resistant epilepsy (search).
Clinical Significance
Focal epilepsy (search), where seizures originate from specific areas of the brain, is the most common form of drug-resistant epilepsy (search). It is often diagnosed in childhood or adolescence and can result in a lifetime of seizures. Uncontrolled seizures can lead to poor cognitive outcomes, depression, decreased social interaction, increased seizure frequency, and sudden unexplained death in epilepsy (SUDEP).
Expert Commentary
"We are excited to reach this important follow up milestone and look forward to FDA review, as well as future peer reviewed publication and presentation of this rigorously collected clinical data," said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer. "The RNS System (search) is the only neuromodulation device that provides stimulation and monitors their response over time. The power of this approach was demonstrated in the randomized controlled and long-term treatment trials. Information from the Post-approval Study will further support physicians as they seek to optimize care for drug-resistant focal epilepsy (search) patients."
About the RNS System
The RNS System (search) is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform aims to improve the standard of care for patients with drug-resistant epilepsy (search) and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Company Statement
"We are excited to have completed the prospective three-year follow up of patients enrolled in this important study and to have submitted the data to the FDA," said Joel Becker, NeuroPace’s Chief Executive Officer. "As the leader in the field of responsive neurostimulation to treat drug-resistant epilepsy (search), we are committed to studying the impact of RNS System (search) treatment over time in order to continue generating high-quality clinical evidence. This study is a key part of our ongoing commitment to provide physicians the information they need to confidently select and treat their patients with the RNS System."